secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2024-09-05T23:59:59+00:00
Accession:  0001213900-24-076184
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.80
Item codes: 5.07, 1.01, 2.01, 5.02, 9.01, 2.02, 3.03, 4.01, 5.01, 5.03, 5.05, 5.06, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

ARCA completes reverse merger with Oruka; combined entity renamed Oruka Therapeutics (ORKA)
--------------------------------------------------------------------------------

- Merger closed: ARCA (shell) merges with private Oruka; Oruka shareholders own ~97.6% of combined company.
- Pre-closing financing raised ~$275M gross from new & existing investors; includes $25M convertible note.
- Special cash dividend of ~$23.4M ($1.613/share) paid to ARCA stockholders on Aug 28, 2024.
- Reverse stock split (1-for-12) effective Sept 3, 2024; post-split common shares outstanding: ~29.4M.
- Combined company changes name to Oruka Therapeutics, Inc. (ORKA) and begins trading on Nasdaq.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000121390024076184/0001213900-24-076184-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea0213193-8k_orukathera.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-076184

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer